Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsSigurdardottir, Sigurveig Th
Arason, Vilhjalmur A
Gruber, William C
MetadataShow full item record
CitationVaccine 2008, 26(33):4178-86
AbstractThis randomized trial compares safety and immunogenicity when vaccinating infants with a pneumococcal-meningococcal conjugate vaccine in two doses vs. three doses. Infants (N=223) received 9vPnC-MnCC (CRM197-conjugated pneumococcal serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F and meningococcal C polysaccharides) either at 3 and 5 or 3, 4 and 5 months and a booster with either 9vPnC-MnCC or 23-valent pneumococcal-polysaccharide vaccine (23vPPS) and CRM197-MnCC, at 12 months. Safety was monitored and IgG measured at 3, 6, 12 and 13 months in all subjects and serum bactericidal activity (SBA) in half. The 9vPnC-MnCC vaccine was safe and induced significant IgG to all components. Three doses induced higher antibody GMCs (geometric mean concentrations) at 6 months to seven of nine pneumococcal serotypes. This was most significant for 6B and 23F (p<0.001), that also showed lower rate of responders >0.35 (6B, 23F) and >0.5mug/mL (6B). Antibody GMCs remained lower following 9vPnC-MnCC booster in subjects primed with two doses although only significant for serotype 18C. Significant memory responses were observed 1 week after the 23vPPS toddler dose. MnCC-IgG GMC was lower after two doses, however with comparable SBA. This study shows that the 9vPnC-MnCC vaccine is safe and induces successful immunological memory, whether given in two or three primary doses.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines.
- Authors: Wysocki J, Tansey S, Brachet E, Baker S, Gruber W, Giardina P, Arora A
- Issue date: 2010 Nov 16
- Immunology of combining CRM(197) conjugates for Streptococcus pneumoniae, Neisseria meningitis and Haemophilus influenzae in Chilean infants.
- Authors: Lagos R, Munoz A, Levine MM, Watson W, Chang I, Paradiso P
- Issue date: 2009 Apr 14
- Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.
- Authors: Diez-Domingo J, Gurtman A, Bernaola E, Gimenez-Sanchez F, Martinon-Torres F, Pineda-Solas V, Delgado A, Infante-Marquez P, Liang JZ, Giardina PC, Gruber WC, Emini EA, Scott DA
- Issue date: 2013 Nov 4
- Immunogenicity and safety of CRM₁₉₇ conjugated 9-valent pneumococcal and meningococcal C combination vaccine in healthy infants.
- Authors: Mallet E, Brachet E, Fernsten P, Laudat F, Razmpour A, Gruber WC, 139-501 Study Group.
- Issue date: 2011 Aug 5
- Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants.
- Authors: Rennels MB, Edwards KM, Keyserling HL, Reisinger K, Blatter MM, Quataert SA, Madore DV, Chang I, Malinoski FJ, Hackell JG, Paradiso PR
- Issue date: 2001 Feb